APOE4 homozygous Alzheimer’s disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
_page-0001.jpg)
Alzheimer's disease (AD) is a
progressive neurodegenerative disease associated with cognitive decline and is
the most common form of dementia in the elderly. Approximately 13% of people
over the age of 65 and 45% over the age of 85 are estimated to have AD. The
imbalance between the production and clearance of amyloid-β (Aβ) peptides in
the brain results in the accumulation and aggregation of Aβ. The toxic Aβ
aggregates in the form of soluble Aβ oligomers, intraneuronal Aβ, and amyloid
plaques injure synapses and ultimately cause neurodegeneration and dementia.
The toxicity of Aβ seems to depend on the presence of microtubule-associated
protein tau, the hyperphosphorylated forms of which aggregate and deposit in AD
brains as neurofibrillary tangles. Aβ is composed of 40 or 42 amino acids and
is generated through proteolytic cleavage of the amyloid precursor protein.
Early-onset familial AD, which typically develops before the age of 65 years
and accounts for only a small portion (<1%) AD cases, is primarily caused by
overproduction of Aβ owing to mutations in either the APP gene or genes
encoding presenilin 1 (PSEN1) or presenilin 2 (PSEN2), essential components of
the γ-secretase complexes responsible for cleavage and release of Aβ.
- The ε4 allele of the apolipoprotein E (APOE) gene is the
strongest risk factor for LOAD.
- The human APOE gene exists as three polymorphic alleles ε2,
ε3, and ε4, which have a worldwide frequency of 8.4%, 77.9%, and 13.7%,
respectively. However, the frequency of the ε4 allele is dramatically
increased to ~40% in patients with AD.
Thelansis’s “APOE4 homozygous
Alzheimer’s disease (AD) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential APOE4
homozygous Alzheimer’s disease (AD) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of APOE4 homozygous Alzheimer’s disease (AD) across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
APOE4 homozygous Alzheimer’s disease
(AD) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment